Insights

Analysis and research from the Exploristics team

Statistical Insights

How clinical trial simulation Software led to better decision making

How new technologies can update clinical trial approaches.

Embedding New Technologies into Clinical Studies

How new technologies can update clinical trial approaches.

Finding the right fixed, fractional or full time model.

The best strategies for effective partner oversight.

experiment

Spoiler alert it’s not “what is the sample size?”!

How statisticians can get you investor ready

How statisticians hold the key to more informed develpment decisions.

Respiratory medicine presents a unique set of challenges for clinical researchers and healthcare professionals.

VUCA

Why choosing the right CRO is crucial in a VUCA world.

How using synthetic control arms can help overcome development challenges.

How involving patients in defining estimands can improve trial engagement.

Thinking blocks

How embracing diverse approaches can help teams navigate the challenges of drug development.

Question mark dice

The Power of Decision Analysis

Semmelweiss

Six ways to make it easier.

Good clinical practise

Examining the impact for drug developers.

Budding Plants

What are the pros and cons of hiring your own statistician?

Vasa warship

Four design insights from the sinking of the Vasa

What a p value does and does not tell you.

How putting patients at the heart of clinical development will improve it.

How lessons from the past and from failure can provide the foundation to future success.

Good games and mighty models

How did statisticians fare against our simulations in our higher/lower gaming app at the PSI Conference?

I’ve got the power – or have I?

Why it’s important to differentiate between power and probability of success.

Unlocking valuable insights from the virtual world

How statisticians hold the key to more informed develpment decisions.

From cars to clinical trials: how simulation can improve design

What Pharma can learn from car manufacturing.

One size does not fit all

Why simple sample size calculations are just the first step in delivering more agile statistical solutions.

Shifting the development paradigm with innovative trial design

What is needed to move the dial on the use of innovative trial designs?

Birth of the Data Science Team at Exploristics

How building models opened up new possibilities.

Disparate and Desperate – curse of the diminishing N

Why more data does not always mean useful data.

Are external control arms worth the extra effort?

Review of the latest FDA guidance.

It’s not rare to have a rare disease

How novel approaches to clinical trial design and analysis supports delivery of treatments for rare diseases.

Pharma’s Road to Damascus? Learnings from the COVID-19 Pandemic

How the pandemic revealed the need to reassess development approaches.

Synthetic Control Arms: Making the leap beyond the gold standard

How synthetic control arms can add another dimension to clinical trials.

Connections and correlations, interactions and interrelationships.

How a better understanding of mutual relationships improves clinical trial design.

Interactive visualisations are the future for effective collaborations

How data visualisation supports collaborative decision-making.

Daring to be Different

How investment in R&D and people plays dividends in innovation.

PSI Conference 2022, Gothenburg Sweden

Industry insights into the hot topics of estimands, adaptive designs and real-world data.

Counting the Costs of Clinical Trials: Why Rethinking Trial Design Matters

Why investing in clinical trial design is a more cost-effective and ethical approach.

Estimands – The “what” and the “how” of drug discovery

How estimands help align study objectives with clinical trial design.

Embedding New Technologies into Clinical Studies

How new technologies can update clinical trial approaches.

Developments in Digital Data

How early engagement with statisticians can help navigate big data.

Why Simulation is Needed to Optimise Both Adaptive & Fixed Clinical Trial Designs

How simulation can be used to identify risks for all types of clinical trial designs.

Simulation-can-address-recruitment-challenges

How using simulation to design clinical trials can help with recruitment.

How the pandemic has heightened interest in unlocking the value of RWD.

Designing-clinical-studies-for-success-and-not-failure

How engaging with statisticians early in design process builds in more success.

Going Synthetic with Real-World Data

How synthetic data offers a solution to unleashing powerful insights from real-world data.

The liberation of real-world data

How unlocking data insights from the real world will help us to see the bigger picture.

Belfast City Centre

Why Belfast is a great place to set up a life science business.

Statistical Insights: Why Getting Smaller Doesn’t Mean Thinking Smaller

How being part of a small company offers agility and creativity.

Clinical-trials-after-COVID-19

How the pandemic has been the disruptor that industry needed.

covid-19

How the life science sector has risen to the challenge of COVID-19.

Statistical Insights

How clinical trial simulation Software led to better decision making

How new technologies can update clinical trial approaches.

Embedding New Technologies into Clinical Studies

How new technologies can update clinical trial approaches.

Finding the right fixed, fractional or full time model.

The best strategies for effective partner oversight.

experiment

Spoiler alert it’s not “what is the sample size?”!

How statisticians can get you investor ready

How statisticians hold the key to more informed develpment decisions.

Respiratory medicine presents a unique set of challenges for clinical researchers and healthcare professionals.

VUCA

Why choosing the right CRO is crucial in a VUCA world.

How using synthetic control arms can help overcome development challenges.

How involving patients in defining estimands can improve trial engagement.

Thinking blocks

How embracing diverse approaches can help teams navigate the challenges of drug development.

Question mark dice

The Power of Decision Analysis

Semmelweiss

Six ways to make it easier.

Good clinical practise

Examining the impact for drug developers.

Budding Plants

What are the pros and cons of hiring your own statistician?

Vasa warship

Four design insights from the sinking of the Vasa

What a p value does and does not tell you.

How putting patients at the heart of clinical development will improve it.

How lessons from the past and from failure can provide the foundation to future success.

Good games and mighty models

How did statisticians fare against our simulations in our higher/lower gaming app at the PSI Conference?

I’ve got the power – or have I?

Why it’s important to differentiate between power and probability of success.

Unlocking valuable insights from the virtual world

How statisticians hold the key to more informed develpment decisions.

From cars to clinical trials: how simulation can improve design

What Pharma can learn from car manufacturing.

One size does not fit all

Why simple sample size calculations are just the first step in delivering more agile statistical solutions.

Shifting the development paradigm with innovative trial design

What is needed to move the dial on the use of innovative trial designs?

Birth of the Data Science Team at Exploristics

How building models opened up new possibilities.

Disparate and Desperate – curse of the diminishing N

Why more data does not always mean useful data.

Are external control arms worth the extra effort?

Review of the latest FDA guidance.

It’s not rare to have a rare disease

How novel approaches to clinical trial design and analysis supports delivery of treatments for rare diseases.

Pharma’s Road to Damascus? Learnings from the COVID-19 Pandemic

How the pandemic revealed the need to reassess development approaches.

Synthetic Control Arms: Making the leap beyond the gold standard

How synthetic control arms can add another dimension to clinical trials.

Connections and correlations, interactions and interrelationships.

How a better understanding of mutual relationships improves clinical trial design.

Interactive visualisations are the future for effective collaborations

How data visualisation supports collaborative decision-making.

Daring to be Different

How investment in R&D and people plays dividends in innovation.

PSI Conference 2022, Gothenburg Sweden

Industry insights into the hot topics of estimands, adaptive designs and real-world data.

Counting the Costs of Clinical Trials: Why Rethinking Trial Design Matters

Why investing in clinical trial design is a more cost-effective and ethical approach.

Estimands – The “what” and the “how” of drug discovery

How estimands help align study objectives with clinical trial design.

Embedding New Technologies into Clinical Studies

How new technologies can update clinical trial approaches.

Developments in Digital Data

How early engagement with statisticians can help navigate big data.

Why Simulation is Needed to Optimise Both Adaptive & Fixed Clinical Trial Designs

How simulation can be used to identify risks for all types of clinical trial designs.

Simulation-can-address-recruitment-challenges

How using simulation to design clinical trials can help with recruitment.

How the pandemic has heightened interest in unlocking the value of RWD.

Designing-clinical-studies-for-success-and-not-failure

How engaging with statisticians early in design process builds in more success.

Going Synthetic with Real-World Data

How synthetic data offers a solution to unleashing powerful insights from real-world data.

The liberation of real-world data

How unlocking data insights from the real world will help us to see the bigger picture.

Belfast City Centre

Why Belfast is a great place to set up a life science business.

Statistical Insights: Why Getting Smaller Doesn’t Mean Thinking Smaller

How being part of a small company offers agility and creativity.

Clinical-trials-after-COVID-19

How the pandemic has been the disruptor that industry needed.

covid-19

How the life science sector has risen to the challenge of COVID-19.

Statistical Insights

How clinical trial simulation Software led to better decision making

How new technologies can update clinical trial approaches.

Embedding New Technologies into Clinical Studies

How new technologies can update clinical trial approaches.

Finding the right fixed, fractional or full time model.

The best strategies for effective partner oversight.

experiment

Spoiler alert it’s not “what is the sample size?”!

How statisticians can get you investor ready

How statisticians hold the key to more informed develpment decisions.

Respiratory medicine presents a unique set of challenges for clinical researchers and healthcare professionals.

VUCA

Why choosing the right CRO is crucial in a VUCA world.

How using synthetic control arms can help overcome development challenges.

How involving patients in defining estimands can improve trial engagement.

Thinking blocks

How embracing diverse approaches can help teams navigate the challenges of drug development.

Question mark dice

The Power of Decision Analysis

Semmelweiss

Six ways to make it easier.

Good clinical practise

Examining the impact for drug developers.

Budding Plants

What are the pros and cons of hiring your own statistician?

Vasa warship

Four design insights from the sinking of the Vasa

What a p value does and does not tell you.

How putting patients at the heart of clinical development will improve it.

How lessons from the past and from failure can provide the foundation to future success.

Good games and mighty models

How did statisticians fare against our simulations in our higher/lower gaming app at the PSI Conference?

I’ve got the power – or have I?

Why it’s important to differentiate between power and probability of success.

Unlocking valuable insights from the virtual world

How statisticians hold the key to more informed develpment decisions.

From cars to clinical trials: how simulation can improve design

What Pharma can learn from car manufacturing.

One size does not fit all

Why simple sample size calculations are just the first step in delivering more agile statistical solutions.

Shifting the development paradigm with innovative trial design

What is needed to move the dial on the use of innovative trial designs?

Birth of the Data Science Team at Exploristics

How building models opened up new possibilities.

Disparate and Desperate – curse of the diminishing N

Why more data does not always mean useful data.

Are external control arms worth the extra effort?

Review of the latest FDA guidance.

It’s not rare to have a rare disease

How novel approaches to clinical trial design and analysis supports delivery of treatments for rare diseases.

Pharma’s Road to Damascus? Learnings from the COVID-19 Pandemic

How the pandemic revealed the need to reassess development approaches.

Synthetic Control Arms: Making the leap beyond the gold standard

How synthetic control arms can add another dimension to clinical trials.

Connections and correlations, interactions and interrelationships.

How a better understanding of mutual relationships improves clinical trial design.

Interactive visualisations are the future for effective collaborations

How data visualisation supports collaborative decision-making.

Daring to be Different

How investment in R&D and people plays dividends in innovation.

PSI Conference 2022, Gothenburg Sweden

Industry insights into the hot topics of estimands, adaptive designs and real-world data.

Counting the Costs of Clinical Trials: Why Rethinking Trial Design Matters

Why investing in clinical trial design is a more cost-effective and ethical approach.

Estimands – The “what” and the “how” of drug discovery

How estimands help align study objectives with clinical trial design.

Embedding New Technologies into Clinical Studies

How new technologies can update clinical trial approaches.

Developments in Digital Data

How early engagement with statisticians can help navigate big data.

Why Simulation is Needed to Optimise Both Adaptive & Fixed Clinical Trial Designs

How simulation can be used to identify risks for all types of clinical trial designs.

Simulation-can-address-recruitment-challenges

How using simulation to design clinical trials can help with recruitment.

How the pandemic has heightened interest in unlocking the value of RWD.

Designing-clinical-studies-for-success-and-not-failure

How engaging with statisticians early in design process builds in more success.

Going Synthetic with Real-World Data

How synthetic data offers a solution to unleashing powerful insights from real-world data.

The liberation of real-world data

How unlocking data insights from the real world will help us to see the bigger picture.

Belfast City Centre

Why Belfast is a great place to set up a life science business.

Statistical Insights: Why Getting Smaller Doesn’t Mean Thinking Smaller

How being part of a small company offers agility and creativity.

Clinical-trials-after-COVID-19

How the pandemic has been the disruptor that industry needed.

covid-19

How the life science sector has risen to the challenge of COVID-19.

Statistical Insights

How clinical trial simulation Software led to better decision making

How new technologies can update clinical trial approaches.

Embedding New Technologies into Clinical Studies

How new technologies can update clinical trial approaches.

Finding the right fixed, fractional or full time model.

The best strategies for effective partner oversight.

experiment

Spoiler alert it’s not “what is the sample size?”!

How statisticians can get you investor ready

How statisticians hold the key to more informed develpment decisions.

Respiratory medicine presents a unique set of challenges for clinical researchers and healthcare professionals.

VUCA

Why choosing the right CRO is crucial in a VUCA world.

How using synthetic control arms can help overcome development challenges.

How involving patients in defining estimands can improve trial engagement.

Thinking blocks

How embracing diverse approaches can help teams navigate the challenges of drug development.

Question mark dice

The Power of Decision Analysis

Semmelweiss

Six ways to make it easier.

Good clinical practise

Examining the impact for drug developers.

Budding Plants

What are the pros and cons of hiring your own statistician?

Vasa warship

Four design insights from the sinking of the Vasa

What a p value does and does not tell you.

How putting patients at the heart of clinical development will improve it.

How lessons from the past and from failure can provide the foundation to future success.

Good games and mighty models

How did statisticians fare against our simulations in our higher/lower gaming app at the PSI Conference?

I’ve got the power – or have I?

Why it’s important to differentiate between power and probability of success.

Unlocking valuable insights from the virtual world

How statisticians hold the key to more informed develpment decisions.

From cars to clinical trials: how simulation can improve design

What Pharma can learn from car manufacturing.

One size does not fit all

Why simple sample size calculations are just the first step in delivering more agile statistical solutions.

Shifting the development paradigm with innovative trial design

What is needed to move the dial on the use of innovative trial designs?

Birth of the Data Science Team at Exploristics

How building models opened up new possibilities.

Disparate and Desperate – curse of the diminishing N

Why more data does not always mean useful data.

Are external control arms worth the extra effort?

Review of the latest FDA guidance.

It’s not rare to have a rare disease

How novel approaches to clinical trial design and analysis supports delivery of treatments for rare diseases.

Pharma’s Road to Damascus? Learnings from the COVID-19 Pandemic

How the pandemic revealed the need to reassess development approaches.

Synthetic Control Arms: Making the leap beyond the gold standard

How synthetic control arms can add another dimension to clinical trials.

Connections and correlations, interactions and interrelationships.

How a better understanding of mutual relationships improves clinical trial design.

Interactive visualisations are the future for effective collaborations

How data visualisation supports collaborative decision-making.

Daring to be Different

How investment in R&D and people plays dividends in innovation.

PSI Conference 2022, Gothenburg Sweden

Industry insights into the hot topics of estimands, adaptive designs and real-world data.

Counting the Costs of Clinical Trials: Why Rethinking Trial Design Matters

Why investing in clinical trial design is a more cost-effective and ethical approach.

Estimands – The “what” and the “how” of drug discovery

How estimands help align study objectives with clinical trial design.

Embedding New Technologies into Clinical Studies

How new technologies can update clinical trial approaches.

Developments in Digital Data

How early engagement with statisticians can help navigate big data.

Why Simulation is Needed to Optimise Both Adaptive & Fixed Clinical Trial Designs

How simulation can be used to identify risks for all types of clinical trial designs.

Simulation-can-address-recruitment-challenges

How using simulation to design clinical trials can help with recruitment.

How the pandemic has heightened interest in unlocking the value of RWD.

Designing-clinical-studies-for-success-and-not-failure

How engaging with statisticians early in design process builds in more success.

Going Synthetic with Real-World Data

How synthetic data offers a solution to unleashing powerful insights from real-world data.

The liberation of real-world data

How unlocking data insights from the real world will help us to see the bigger picture.

Belfast City Centre

Why Belfast is a great place to set up a life science business.

Statistical Insights: Why Getting Smaller Doesn’t Mean Thinking Smaller

How being part of a small company offers agility and creativity.

Clinical-trials-after-COVID-19

How the pandemic has been the disruptor that industry needed.

covid-19

How the life science sector has risen to the challenge of COVID-19.

Want to find out more? Get in touch.

Learn how KerusCloud helped raise US$30 million in a subsequent financing round

X